Your session is about to expire
← Back to Search
CapTem Plus Radioembolization for Neuroendocrine Tumor Liver Metastases(CapTemY90 Trial)
CapTemY90 Trial Summary
This trial is testing a combination of drugs to treat neuroendocrine tumors that have spread to the liver. The drugs are capecitabine, temozolomide, and yttrium-90 radioembolization. The study is to see if this combination is more effective than other treatments and has fewer side effects.
- Neuroendocrine Tumors
- Liver Metastases
CapTemY90 Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
CapTemY90 Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
CapTemY90 Trial Design
Find a Location
Who is running the clinical trial?
- You cannot have contrast-enhanced MRI or CT scans.You are expected to live for at least 6 more months.You have had surgery or procedures involving the bile duct or the opening between the small intestine and the bile duct.You cannot take capecitabine or temozolomide due to medical reasons.You have received a specific type of treatment called transarterial embolization or radioembolization in the past.You have a blockage in the main vein that carries blood to your liver.
- Group 1: CapTemY90
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Are the combination of Capecitabine tablets, temozolomide tablets, and SIR-Spheres supported by a federal stamp of approval?
"On the basis of Phase 2 data, our team at Power rated capecitabine tablets + temozolomide tablets + SIR-Spheres a score of two for safety; albeit there is evidence to support its security, no studies have confirmed its efficacy."
Are there any reports detailing the effects of taking Capecitabine tablets in combination with temozolomide tablets and SIR-Spheres?
"Currently, 531 studies involving the combination of Capecitabine tablets + temozolomide tablets + SIR-Spheres are actively recruiting participants. Of these trials, 149 have reached Phase 3 and a total of 16,516 locations across the world are running them. Adelaide in South Australia is among the sites hosting these investigations."
Is this experimental protocol new to the field?
"Since 2002, comprehensive research has been conducted into the effects of Capecitabine tablets + temozolomide tablets + SIR-Spheres. The initial trial was funded by Schering-Plough and involved 60 participants—prompting Phase 2 drug approval in due course. Nowadays, 531 active studies are taking place across 70 nations and 2291 cities."
Are researchers currently looking for volunteers to join this experiment?
"Affirmative. Clinicaltrials.gov reveals that this research endeavour, first posted on November 1st 2021, is seeking volunteers at present. The clinical trial requires 55 individuals to register from a single medical centre."
How many individuals are enrolled in this investigation?
"Affirmative. clinicaltrials.gov has the latest information on this medical investigation, which was originally posted in November 2021 and last modified in October of that same year. The exploration is seeking 55 individuals to participate at a single trial centre."
What disease or condition would necessitate treatment with Capecitabine tablets, temozolomide tablets and SIR-Spheres?
"For managing progression of the illness, Capecitabine tablets + temozolomide tablets + SIR-Spheres is often recommended. Additionally, this combination can be advantageous for patients dealing with nitrosourea treatment, advance directives and refractory advanced mycosis fungoides."
Share this study with friends